您现在的位置: 首页> 研究主题> 聚-DL-乳酸

聚-DL-乳酸

聚-DL-乳酸的相关文献在1999年到2017年内共计86篇,主要集中在基础医学、外科学、口腔科学 等领域,其中期刊论文82篇、会议论文3篇、专利文献95252篇;相关期刊45种,包括中山大学学报(自然科学版)、中国生物医学工程学报、临床骨科杂志等; 相关会议3种,包括2011年第十一届上海地区医用生物材料研讨会、第三届全国创伤骨科学术会暨组织修复与重建新技术研讨会、第二届中华骨科杂志论坛等;聚-DL-乳酸的相关文献由261位作者贡献,包括全大萍、熊成东、王远亮等。

聚-DL-乳酸—发文量

期刊论文>

论文:82 占比:0.09%

会议论文>

论文:3 占比:0.00%

专利文献>

论文:95252 占比:99.91%

总计:95337篇

聚-DL-乳酸—发文趋势图

聚-DL-乳酸

-研究学者

  • 全大萍
  • 熊成东
  • 王远亮
  • 郑启新
  • 卢泽俭
  • 廖凯荣
  • 李世普
  • 杜靖远
  • 罗彦凤
  • 郭晓东
  • 期刊论文
  • 会议论文
  • 专利文献

搜索

排序:

年份

    • 银保; 汤逊; 熊成东; 何祺; 尹劲
    • 摘要: 目的 观察3种可吸收柱状材料植入动物体内的组织相容性,为临床应用提供依据.方法 选择60只新西兰大白兔,按随机数字表法分成3组,每组20只,雌雄各半,分别将6%β-磷酸三钙(β-TCP)/聚-D,L-乳酸(PDLLA)、12%β-TCP/PDLLA和纯PDLLA 3种可吸收柱状材料植入兔右侧股骨髁及臀外侧肌肉内;左侧为对照组.术后4、8、12、16及24周取出材料进行大体观察和光镜观察.6%β-TCP/PDLLA复合材料行植入前及术后8、16、24周电镜观察.结果 所有动物术后一般情况良好.术后伤口无红肿,均一期愈合,2周内缝线自行脱落.实验周期内无感染、化脓及组织液化.24周时6%β-TCP/PDLLA组柱状材料,部分被新生骨组织吸收替代,骨小梁排列较整齐,可见哈弗管及致密骨形成;12% β-TCP/PDLLA组柱状材料见大量新生骨组织替代,也可见致密骨形成,但其降解吸收相对较快;纯PDLLA组柱状材料骨组织形成相比另2组成骨量较少.6% β-TCWPDLLA材料24周时电镜下材料内层水解明显,因被降解吸收,多部位出现塌陷而结构紊乱破损,内部见大量无裂隙的扭曲样改变.对照组24周时骨小梁进行改建,可见致密的板层骨,但仍有较多腔隙.结论 3种可吸收柱状材料的组织相容性良好,6% β-TCP/PDLLA材料降解过程较另2组材料平稳,可能是较为理想的椎体重建可吸收复合材料.
    • 朱水涛; 王群波; 邵高海; 卢旻鹏; 余雨; 李波
    • 摘要: 目的 评估聚D,L-乳酸(PDLLA)三维多孔支架的体外细胞相容性,探讨其作为骨组织工程支架类材料的可行性,为进一步进行体内试验提供依据.方法 将分离、获取的第3代骨髓间充质干细胞(BMSCs)按随机数字表法分成5组(0,3,6,9,12周组),分别用含体积分数20%降解液(0,3,6,9,12周时的PDLLA降解液)的细胞培养液和成骨诱导分化培养液进行细胞培养(以不含有降解液的细胞培养液或者成骨诱导分化培养液培养组为对照组,即0周组),从BMSCs的毒性、活力、成骨分化能力等方面定量评估PDLLA支架材料的细胞相容性;将分离、获取的第3代BMSCs种植于PDLLA支架材料上,定期进行扫描电子显微镜观察,从不同时相点细胞在PDLLA材料表面的生长情况定性评估PDLLA支架材料的细胞相容性. 结果 各组与对照组比较均未发现对细胞具有明显的毒性作用;各组均未发现对细胞的活力具有明显的负面影响(t3=-0.441,P=0.671;t6=1.596,P=0.154;t9=-0.492,P=0.636;t12=-1.135,P=0.283);各组细胞ALP染色和钙结节染色结果均表现为阳性,ALP活性定量检测和Ⅰ型胶原蛋白表达的定量检测与对照组之间差异均无统计学意义.扫描电镜结果显示,BMSCs在PDLLA三维多孔支架材料上呈现较好的贴壁生长.结论 PDLLA支架材料对BMSCs具有较好的体外相容性,可以作为一种骨组织工程支架类材料进行后续的体内试验.%Objective To investigate the in vitro cytocompatibility of three-dimensional porous scaffolds of poly-D,L-lactic acid (PDLLA) and discuss the feasibility of PDLLA as a scaffold for bone tissue engineering.Methods BMSCs of the third passage were seeded on osteogenetic differentiation medium or culture medium containing 20% volume fraction degraded liquid (PDLLA degradation liquid of 0,3,6,9,and 12 weeks) according to the random number table.Osteogenetic differentiation medium or culture medium without PDLLA was used as controls.Cell viability,cytotoxicity,and osteogenic differentiation were detected for study on cytocompatibility of PDLLA.Scanning electron microscopy was used to observe the growth of BMSCs on the surface of PDLLA scaffolds.Results PDLLA scaffolds presented no significant cytotoxic on the growth of BMSCs.PDLLA scaffolds had no negative effect on cell viability compared with the controls (t3 =-0.441,P =0.671; t6 =1.596,P =0.154; t9 =-0.492,P =0.636; t12 =-1.135,P=0.283).ALP staining and calcium nodule staining were positive and there were no significant differences in ALP and collagen Ⅰ protein quantitative detection compared with the controls.BMSCs grew well on the inner surface of the PDLLA three-dimensional porous scaffolds.Conclusion Three-dimensional porous scaffolds of PDLLA present good cytocompatibility in vitro and can be used as bone tissue engineering scaffolds for subsequent in vivo research.
    • 孟锐; 李晓刚; 刘双清; 朱锐; 柏连阳
    • 摘要: 分别以相对分子质量为25 000、60000、100 000的聚(D,L)乳酸(PDLLA)为壁材,PVA-1788为乳化剂,采用乳化溶剂挥发法制备PDLLA-毒死蜱微胶囊,考察工艺条件对微胶囊粒径的影响,通过光学显微镜、扫描电子显微镜、激光粒度分布仪、高效液相色谱(HPLC)等表征PDLLA-毒死蜱微胶囊性能,并采用柱层析法评价了3种PDLLA-毒死蜱微胶囊的缓释性能.结果表明,工艺条件对微胶囊的粒径有显著影响,当PVA-1788质量分数为1.25%,连续相与有机相体积比为4∶5,PDLLA与毒死蜱质量比为2∶1时,可获得球形规整、粒径较小的微胶囊.PDLLA相对分子质量的改变对微胶囊的外观、粒径大小及分布、载药量和包覆率均无显著影响.3种PDLLA微胶囊对毒死蜱均具有明显的缓释效应,释药19 d,药物累积释放量分别为88.76%、76.74%、65.64%,其中,相对分子质量25 000的PDLLA-毒死蜱微胶囊释药速率最快.%Poly-D,L-Lactides (PDLLA1, PDLLA2 and PDLLA3) with molecular weight of 25 000, 60 000 and 100 000 respectively were used as coating material and, polyvinyl alcohol (PVA-1788) was used as emulsifier to prepare PDLLA-Chlopyrifos microcapsule by emulsion solvent volatilization method. The effects of process conditions were studied. The performance of PDLLA-Chlopyrifos microcapsule was characterized by optical microscope, scanning electron microscope, laser particle size distribution device and high performance liquid chromatograph and the performance of sustained release of three kinds of PDLLA-Chlopyrifos microcapsules was studied by column chromatography. The results showed that process conditions had a significant effect on microcapsule diameter, and microcapsule with regular sphere and small diameter could be obtained when PVA-1788 concentration was 1.25%, volume ratio of continuous phase and organic phase was 4.5 and weight ratio of PDLLA and Chlopyrifos was 2:1. The molecular weight of PDLLA had little effect on appearance, diameter and distribution of microcapsule. Three PDLLA-Chlopyrifos microcapsules showed significant sustained-release effect. And the accumulated release of PDLLA1, PDLLA2and PDLLA3 19 d after administering were 88.76%, 76.74% and 65.64%, respectively, among which PDLLA1 with the lowest molecular weight (25 000) had the fastest speed of release.
    • 银保; 汤逊; 熊成东; 尹劲; 何祺
    • 摘要: Objective To explore three material ( 6% β-TCP/PDLLA, 12% β-TCP/PDLLA, PDLLA ) centrum-vertebra-fracture-repairing absorbable supporting plugger, CASP implantation in the histocompatibility and imaging changes,for further clinical application to provide the basis of animal experiments. Methods Select 60 New Zealand white rabbits, made of materials in three of CASP were implanted in the gluteus maximus. 4,8,12,16 and 24 weeks after removal materials,to the naked eye observation,biopsy, HE staining. After 4 weeks, 12 weeks,24 weeks perturbation X-ray at each time point. Results Histocompatibility of three absorbable material were good, the organization had no adverse reaction;The histological observation results were consistent with the normal bone healing process,X-ray showed significant degradation over time(6% β-TCP/PDLLA, 12% β-TCP/PDLLA) , in line with its degradation process and the fracture healing process. Conclusions Three different formulations centrum-vertebra-fracture-repairing absorbable supporting plugger 6% TCP/PDLLA composite support in vertebral histocompatibility are better than the other two groups, 12%TCP/PDLLA degradation rate is faster than the other two groups.%目的 探讨三种材料(6%β-TCP/PDLLA,12%β-TCP/PDLLA,纯PDLLA)的可吸收椎体内支撑器(CASP)植入体内的组织相容性及影像学变化,为进一步临床应用提供动物实验的基础.方法 选择60只新西兰大白兔,用三种材料制成CASP分别植入臀大肌内.术后4、8、12、16及24周取出材料,行肉眼观察、组织切片,HE染色.术后4周、8周、12周、24周各时间点摄X线片.结果 三种可吸收材料组织相容性良好,对组织无不良反应;组织学观察结果基本符合正常骨愈合过程,X线显示随时间推移(6%β-TCP/PDLLA,12%β-TCP/PDLLA)出现明显降解,其降解过程与骨折的愈合过程基本符合.结论 三种不同配方的可吸收椎体内支撑器中6%TCP/PDLLA复合材料的组织相容性优于其余两组,12%TCP/PDLLA降解速度快于其余两组.
    • 傅亚; 胡承波; 许静; 姚波; 卓凤萍; 王远亮
    • 摘要: Electrospun poly(D,L,lactic acid)(PDLLA) superfine fiber has become one of the hot spots regarding scaffolds materials in tissue engineering,due to its high porosity,tunable pore size and structure,as well as good biocompatibility.In this study,we investigated the factors including concentration,solution feeding rate,applied voltage and drying methods that affecting the morphology of PDLLA fibrous scaffolds.The optimum process parameters were determined: solution concentration was 0.20g/mL,solution feeding rate was 0.8mL/h,applied voltage was 12kV.After lyophilization,uniformly distributed PDLLA fibers with diameters of 500-900nm were obtained.In vitro cell morphology observation showed that PDLLA fibrous scaffolds having good cytocompatibility.%静电纺丝法制备的聚(D,L-乳酸)超细纤维具有孔隙率高、孔径/结构可调、生物相容性良好等特点,已成为组织工程支架材料研究的热点。探讨了纺丝溶液浓度、流量、电压、干燥方式等影响聚(D,L-乳酸)纤维支架形貌的因素,确定了最佳工艺参数为纺丝溶液浓度为0.20g/mL,流速为0.8mL/h,电压为12kV,经真空冷冻干燥,可获得分布比较均匀,直径大多为500~900nm的聚乳酸纤维。体外细胞形貌观察表明聚(D,L-乳酸)纤维支架具有良好的细胞相容性。
    • 傅亚; 钱智勇; 黄美娜; 胡承波; 姚波; 任凌燕; 王远亮
    • 摘要: 通过自由基聚合反应将马来酸酐接枝到聚(D,L-乳酸)(PDLLA)侧链上,然后通过引入的活性反应基团马来酸酐与甘油磷脂胆碱反应,实现磷脂胆碱对聚乳酸的整体仿生修饰。采用红外光谱和核磁共振碳谱对磷脂胆碱修饰聚乳酸进行了表征。生物降解实验表明,该功能化聚乳酸具有明显抑制酸致降解作用。体外细胞形貌观察证实磷脂胆碱修饰的聚乳酸具有良好的细胞相容性。同时,蛋白吸附和血小板粘附实验表明,该聚合物具有良好的血液相容性。该改性聚乳酸可望用作组织工程支架及血液接触类植入体。%The maleic anhydride is grafted onto the side-chain of poly(D, L-lactic acid) (PDLLA)by free radical polymerization firstly. Secondly the maleic anhydride is reacted with glycerophosphorylcholine(GPC). Thus the phospholipid choline bionic chemical modification with PDLLA can be got. It was characterized by fourier trans- form infrared spectroscopy (FT-IR)and^13 C-NMR. Biodegradation test showed that this functional poly(D, L- lactic acid) could significantly inhibit'the acid induced degradation of the PDLLA. In vitro cell morphology ob- servation confirmed that GPC modified PDLLA was cytocompatible. Meanwhile, Protein adsorption test and platelet adhesion test revealed that the GPC modified PDLLA was also hemocompatible. These results suggest that GPC modified PDLLA could be an excellent biocompatible candidate for the development of tissue engineer- ing scaffold and blood contacting implants.
    • 吴锦春; 宋斌; 孙俊英
    • 摘要: 目的 探讨骨髓基质细胞(BMSCs)与聚DL-乳酸/羟基磷灰石(PDLLA/HA)复合后异位成骨的生物学机制,了解其用于骨组织工程支架材料的可行性.方法 将BMSCs与PDLLA/HA复合物植入动物皮下后进行大体观察、组织学染色,观察其成骨过程.结果 一定浓度的BMSCs与PDLLA/HA复合植入动物皮下可产生软骨和骨组织,而单纯材料组未见软骨或骨形成.结论 PDLLA/HA复合BMSCs体内植入后能形成软骨或骨,并随植入时间的延长,软骨或新骨形成增多,PDLLA/ HA可用于骨组织工程的支架材料.%Objective To study the osteogenic mechanism of the composite of bone marrow stromal cells(BMSCs) and PDLLA/HA in vivo and explore their possibility applied as the scaffold material of bone tissue engineering. Methods The composite of BMSCs and PDLLA/HA was implanted in subcutaneous sites in rabbits. All implants were examined by gross observation and underwent histological examination.Results Cartilage and bone are observed in the composites of the BMSCs and PDLLA/HA material in rabbit models.There was not any cartilage and bone formed at control group. Conclusions Cartilage and bone formed after PDLLA/HA composited with BMSCs implanted,cartilage and new bone formed much more followed with time.PDLLA/HA could be used as a scalfold of bone tissue engineering.
    • 钱智勇; 罗彦凤; 傅亚; 张徭尧; 霍润兰; 王远亮
    • 摘要: 以马来酸酐和己二胺为原料制备出了一种新型的马来酰己二胺酸单体(HOOC-MAH-HDA-NH2),然后采用自由基熔融接枝技术将HOOC-MAH-HDA-NH2引入到PDLLA骨架中,形成了结构与己二胺改性聚乳酸(HMPDLLA)相似的MHP-DLLA材料。采用红外光谱(FT-IR)、核磁共振氢谱(1 H NMR)、核磁共振碳谱(13 C NMR)和DEPT 135对HOOC-MAH-HDA-NH2和MHPDLLA的化学结构进行了定性和定量表征。以PDLLA为空白,HMP-DLLA为对照,对MHPDLLA的%A novel synthesis technology was designed in this study: firstly,a new monomer maleic hexanediamine acid(HOOC-MAH-HDA-NH2) was synthesized by reacting maleic anhydride(MAH) with hexanediamine(HDA),which was then incorporated onto poly(DL-lactic acid)(PDLLA) backbone by free radical graft copolymerization.Theoretically,the obtained polymer(MHPDLLA) has similar chemical structure to the hexanediame modified PDLLA(HMPDLLA) obtained by the traditional technology.Results from FT-IR,1H NMR,13C NMR and DEPT135 verified the chemical structures of HOOC-MAH-HDA-NH2 and MHPDLLA.Furthermore,the molecular weights detection via gel permeation chromatography with multi-angle laser light scattering(GPC-MALLS) indicated that,the molecular weight loss of MHPDLLA compared to PDLLA was 33%-34% while HMPDLLA was 66%-68%.This suggested that this new synthesis technology was effective in preventing PDLLA from aminolysis,and may hopefully promoted the applications of MHPDLLA as a base material for preparation of bioactive or biomimetic materials.
    • 刘磊力; 陈长亮; 郑永攒; 李鹏; 陈明辉
    • 摘要: In this study, collagen-modified poly (DL-lactic acid) (PLA) was synthesized by introducing collagen into poly (DL-lactic acid) (PLA). FT-IR, FITC fluorescence labeling method and ninhydrin reaction was used to characterize collagen-modified poly (DL-lactic acid). The results revealed that collagen can be incorporated into the side chain of PLA by means of the said synthesis method. The measurement of water contact angle and wa-ter absorption ratio of collagen-modified PLLA indicated that the hydrophilicity of collagen-modified PLLA was better than that of PLLA.%利用胶原蛋白对聚乳酸进行了化学改性,合成得到胶原蛋白改性聚乳酸.采用红外光谱、FITC标记技术、茚三酮显色法等方法对其结构进行了初步表征.结果表明,采用该合成方法可以将胶原蛋白引入聚乳酸中;测定了胶原蛋白改性聚乳酸的水接触角和吸水率,结果表明胶原蛋白改性聚乳酸的亲水性明显高于聚乳酸.
    • 刘磊力; 陈长亮; 郑永攒; 李鹏; 陈明辉
    • 摘要: 利用胶原蛋白对聚乳酸进行了化学改性,合成得到胶原蛋白改性聚乳酸。采用红外光谱、FITC标记技术、茚三酮显色法等方法对其结构进行了初步表征。结果表明,采用该合成方法可以将胶原蛋白引入聚乳酸中;测定了胶原蛋白改性聚乳酸的水接触角和吸水率,结果表明胶原蛋白改性聚乳酸的亲水性明显高于聚乳酸。
  • 查看更多

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号